Leukemia

NEW ORLEANS — In this video perspective, Richard M. Stone, MD, discusses research presented at ASH Annual Meeting and Exhibition looking at the use of measurable residual disease to guide treatment of patients with acute myeloid leukemia.

The FDA approved zanubrutinib for treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.

NEW ORLEANS — Cumulative anesthesia exposure appeared associated with impairments in neurocognitive function among children with high-risk acute lymphoblastic leukemia, according to study results presented at ASH Annual Meeting and Exposition.

NEW ORLEANS — In this video perspective, Richard M. Stone, MD, discusses research results on blinatumomab presented at ASH Annual Meeting and Exposition.

NEW ORLEANS — A new clinical tool can help identify which patients with clonal hematopoiesis are at highest risk for progression to cancer, according to study results presented at ASH Annual Meeting and Exposition.

NEW ORLEANS — In this video, Aaron T. Gerds, MD, MS, assistant professor at the Cleveland Clinic Taussig Cancer Institute, discusses updated results from the Momentum phase 3 study presented at the ASH Annual Meeting and Exposition.

NEW ORLEANS — Abhay Singh, MD, MPH, of the Cleveland Clinic discusses the results of a study presented here on therapy-related risk factors for the development of myelodysplastic syndrome and acute myeloid leukemia in cancer survivors.

The FDA approved olutasidenib for treatment of certain adults with relapsed or refractory acute myeloid leukemia.

Socioeconomic status had no impact on complete remission rates or overall survival among younger patients who received chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia, study results showed.

Dual administration of CD19- and CD22-directed chimeric antigen receptor T cells conferred a 99% complete remission rate in younger patients with relapsed or high-risk B-cell acute lymphoblastic leukemia, phase 2 study results showed.